Orion's sales up 10% in 2010
This article was originally published in Scrip
Orion of Finland reported a 10% increase in net sales for 2010 to €850 million, including products arising from its own research such as Stalevo for Parkinson's disease, Simdax for heart failure, the Easyhaler (salbutamol) pulmonary drug and Precedex (dexmedetomidine), an intensive care sedative.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.